Медицинская литература. Новинки

 

 

 

 

 

 

ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ ПРИ ТИРЕОТОКСИКОЗЕ – ДЕТЕРМИНАНТЫ РАЗВИТИЯ И СОХРАНЕНИЯ

Вы можете загрузить полный текст статьи в формате pdf

Фибрилляция предсердий является частым нарушением ритма при тиреотоксикозе и может привести к развитию серьезных осложнений (тромбоэмболии, инсульт) и смерти. Изучение факторов, повышающих риск развития фибрилляции предсердий при тиреотоксикозе, продолжается многие годы, но внедрение новых методов обследования и математического анализа позволяет выявить новые детерминанты возникновения фибрилляции и ее сохранения после восстановления эутиреоза. В представленной работе было выполнено ЭхоКГобследование 254 пациентов с болезнью Грейвса и 110 человек с субклиническим тиреотоксикозом. Проведенный анализ позволил выявить ряд новых детерминант развития и сохранения фибрилляции предсердий. Это прежде всего длительность сохранения тиреотоксикоза, концентрический тип гипертрофии левого желудочка. Определен вклад различных факторов в формирование фибрилляции предсердий.

Ключевые слова:
тиреотоксикоз, фибрилляция предсердий, ремоделирование миокарда.

Литература:
1. Бабенко А.Ю. Тиреотоксическая кардиомиопатия: факторы
риска и предикторы развития. Обзоры по клинической фармакологии и лекарственной терапии. 2011; 9 (3): 49–59.
2. Бабенко А.Ю., Гринева Е.Н., Солнцев В.Н., Цой У.А., Шляхто Е.В. Вклад различных факторов в характер поражения
сердца при тиреотоксикозе. Мед. акад. журн. 2012. 10 (1):
6–12.
3. Боровиков В. Statistical искусство анализа данных на компьютере. Для профессионалов. СПб.: Питер, 2001. 656 с.
4. Ланг Т., Сесик М. Как описывать статистику в медицине. Аннотированное руководство для авторов, редакторов и рецензентов. М.: Практическая медицина, 2011. 480 с.
5. Орлов В.Н. Руководство по электрокардиографии. 6-е изд.,
стереот. М.: Мед. информ. агентство, 2007. 525 с.
6. Шустов С.Б., Кицышин В.П. Особенности суточного распределения нарушений ритма у больных с эндокринными кардиомиопатиями. Рус. мед. журн. http://www.rusmg.ru/php/
contents.php?id=9275
7. Auer J., Scheibner P., Mische T. et al. Subclinical hyperthyroidism
as a risk factor for atrial fibrillation. Am. Heart. J. 2001; 142:
838–842.
8. Bahn R.S. et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association
and american association of clinical endocrinologists. Endocrinol.
Pract. 2011; 17: 456–520.
9. Cappola A.R., Fried L.P., Arnold A.M. et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295 (9):
1033–1041.
10. Ching G.W., Franklyn J.A., Stallard T.J. et al. Cardiac hypertrophy
as a result of longterm thyroxine therapy and thyrotoxicosis.
Heart 1996; 75: 363–368.
11. De Simone G. Concentric or eccentric hypertrophy: how clinically
relevant is the difference? Hypertension 2004; 43 (4): 714–715.
12. Donatelli M., Assennato P., Abbadi V. et al. Cardiac changes in subclinical and overt hyperthyroid women: retrospective study. Int.
J. Cardiol. 2003; 90: 159–164.
13. Dorr M., Wolff B., Robinson D.M. et al. The association of thyroid
function with cardiac mass and left ventricular hypertrophy. J.
Clin. Endocrinol. Metab. 2005; 90 (2): 673–677.
14. Dougherty M., Craige E. Apathetic hyperthyroidism presenting as
tricuspid regurgitation. Chest. 1973; 63: 767–772.
15. Dunn M., Alexander J., de Silva R., Hildner F. Antithrombotic therapy in atrial fibrillation. Chest. 1989; 95 (Suppl. 2): 118S–127S.
16. Ganau A., Devereux R.B., Roman M.J. et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J. Am. Coll. Cardiol. 1992; 19: 1550–1558.
17. Flynn R.W.V., McDonald T.M., Jung R.T. et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J. Clin.
Endocrinol. Metab. 2006; 91 (6): 2159–2164
18. Franklyn J.A., Sheppard M.C., Maisonneuve P. Thyroid function
and mortality in patients treated for hyperthyroidism. JAMA 2005;
294 (1): 71–80.
19. Frost L., Vestergaard P., Mosekilde L. Hyperthyroidism and risk of
atrial fibrillation or flutter: a populationbased study. Arch. Intern.
Med. 2004; 164: 1675–1678.
20. Iwasaki T., Naka M., Hiramatsu K. Echocardiographic studies on
the relationship between atrial fibrillation and atrial enlargement in
patients with hyperthyroidism of Graves' disease. Cardiology 1989;
76 (1): 10–17.
21. Lang R.M., Biering M., Devereux R.B. et al. Recommendations for
chamber quantification: a report from the American of Society
Echocardiography's guidelines and standards committee and the
chamber quantification writing group, developed in conjunction
with the European Association of Echocardiography, a branch of
the European Society of Cardiology. J. Am. Soc. Echocardiogr.
2005; 18: 1440–1463.
22. Marcisz C., Jonderko G., Wroblewski T. et al. Left ventricular mass
in patients with hyperthyroidism. Med. Sci Monit. 2006; 12 (11):
481–486.
23. Marti V., Ballester M., Rigla M. et al. Myocardial damage does not
occur in untreated hyperthyroidism unless associated with congestive heart failure. Am. Heart J. 1997. 134 (6): 1133–1137.
24. Marvisi M., Zambrelli P., Brianty M. et al. Pulmonary hypertension
is frequent in hyperthyroidism and normalizes after therapy. Eur. J.
Intern. Med. 2006; 17 (4): 267–271.
25. Merce J., Ferras S., Oltra C. et al. Cardiovascular abnormalities in
hyperthyroidism: A prospective Doppler echocardiographic study.
Am. J. Med. 2005; 118: 126–131.
26. Metso S., Auvinen A., Salmi J. еt al. Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for
hyperthyroidism. Clin. Endocrinol. 2007; 92: 2190–2196.
27. Mintz G., Pizzarello R., Klein I. Enhanced left ventricular diastolic
function in hyperthyroidism: noninvasive assessment and response
to treatment. J. Clin. Endocrinol Metab. 1991; 73: 146–150.
28. Nakazawa H. et al. Is there a place for the late cardioversion of atrial fibrillation? A longterm followup study of patients with postthyrotoxic atrial fibrillation. Eur. Heart J. 2000; 21: 327–333.
29. Nakchbandi I.A., Wirth J.A., Inzucchi S.E. Pulmonary hypertension caused by Graves’ thyrotoxicosis normal pulmonary hemodynamics restored by 131I treatment. Chest. 1999; 116: 1483–1485.
30. Osman F., Daykin J., Sheppard M. et al. Cardiac rhythm abnormalities in thyrotoxicosis — the explanation for excess vascular
mortality. J. Endocrinol. 2000; 164: 321–322.
31. Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988; 19: 15–18.
32. Rubin L.J., Badesch D.B. Thyrotoxicosis as a risk factor for pulmonary arterial hypertension. Ann. Intern. Med. 2006; 144 (3):
222–223.
33. Sandier G., Wilson G. The nature and prognosis of heart disease in
thyrotoxicosis: a review of 150 patients treated with I131. QJM
1959; 28: 347–352.
34. Sheu J.$J., Kang J.$H., Lin H.$C. et al. Hyperthyroidism and risk
of ischemic stroke in young adults. Stroke 2010; 41 (5): 961–966.
35. Siu C.W., Yeung C.Y., Lau C.P. et al. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 2007; 93:
483–487.
36. Soh М.С., Croxson М. Fatal thyrotoxic cardiomyopathy in a young
man. BMJ 2008; 337: 531.
37. Tenerz A., Forberg R., Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J. Intern. Med. 1990;
228: 229–233.
38. Toft A., Boon N. Thyroid disease and the heart. Heart 2000; 84:
455–460.

Determinants of development and preservation of atrial fibrillation at thyrotoxicosis

Atrial fibrillation is a frequent violation of a heart rhythm at thyrotoxicosis and it can determine serious complications (tromboembolia, stroke) and death. The study of factors increasing risk development of atrial fibrillation at thyrotoxicosis is investigating many years but the occurrence of new diagnostic methods and mathematic analysis allows to reveal new determinants of development of atrial fibrillation and its persistence after restoration of euthyreosis. In our research we’ve studied the Echo-cardiography parameters in 254 normotensive patients with a thyrotoxicosis Graves’ disease without any CVD and 110 patients with a subclinical thyrotoxicosis. We detected new factors of risk of atrial fibrillation: the duration of thyrotoxicosis and the left ventricular concentric hypertrophy. The contribution of different factors in development of atrial fibrillation is defined.

Keywords:
thyrotoxicosis, atrial fibrillation, myocardial remodeling